Pursuing bold solutions through neuroscience research

Chris Boerner: As part of Bristol Myers Squibb's vision to transform patients' lives through science, we're committed to the pursuit of breakthrough, bold solutions that address the needs of people living with neurological and neuropsychiatric diseases.

Over 3 billion people live with a neurological condition, making it the leading cause of ill health and disability worldwide.

The brain is the most complex organ in the body.

It is made up of intricate networks of neurons that communicate using a vast number of neurotransmitters.

Dysfunction within this closely regulated system can lead to neurological conditions, making them some of the greatest medical challenges of our time.

Persistent and chronic in nature and often associated with aging, these conditions can be difficult to diagnose and treat effectively, especially in their early stages.

The prolonged mental and functional decline that they cause over many years can dramatically alter the lives of patients, caregivers and family and have a significant impact on healthcare systems.

While there has been some progress, there remain many unmet needs for patients with neurological and neuropsychiatric conditions.

There are limited options for therapies that treat their symptoms or modify their disease.

To help those impacted by devastating conditions such as schizophrenia, multiple sclerosis, Alzheimer's disease, and more, our growing neuroscience franchise is driven by research and clinical development teams working to discover and develop life changing medicines that have the potential to alleviate symptoms, improve function and quality of life, and even modify disease progression.

We established our innovative neuroscience pipeline by combining our deep internal expertise with external partnerships and targeted acquisitions to identify and advance the most promising scientific innovation happening around the world.

This agile neuroscience research and development model has rapidly yielded a broad pipeline of novel drug candidates across a number of therapeutic modalities.

These modalities include oral small molecules to biologics and CAR T therapies, all of which have the potential to deliver meaningful benefits for patients.

Evolution is in our DNA at Bristol Myers Squibb.

We are motivated by the rapid evolution of scientific knowledge within neuroscience, which we are using to discover, develop, and deliver transformative medicines for some of the most challenging diseases of our time.